Browsing Tag
obesity treatment
39 posts
Rhythm Pharmaceuticals’ IMCIVREE hits regulatory speed bump as FDA extends decision timeline into 2026
Find out how Rhythm Pharmaceuticals’ IMCIVREE FDA review delay could shape the rare obesity treatment market in 2026.
Viking Therapeutics’ GLP-1/GIP dual agonist VK2735 impresses at ObesityWeek 2025 with sustained weight-loss efficacy
Find out how Viking Therapeutics’ VK2735 is redefining obesity treatment with sustained clinical results — see what this breakthrough means for patients and investors today!
From GLP-1 to FGF21: How Novo Nordisk’s Akero Therapeutics deal signals a new era in metabolic drug dominance
Novo Nordisk’s $5.2 B Akero deal adds the FGF21 drug efruxifermin to its MASH portfolio. See how it expands the company’s metabolic dominance.
Sen-Jam’s SJP-002C gets FDA-ready CMC milestone as investors eye late-stage trial momentum
Sen-Jam finalizes NDA-ready CMC deliverables for SJP-002C with KVK Tech and expands investor engagement, positioning for Phase 2b/3 trials.
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
Ascletis Pharma completes dosing in U.S. ASC47-semaglutide study for obesity treatment
Ascletis Pharma completes dosing in its ASC47-semaglutide obesity trial. Find out why Q4 2025 data could be a game changer for muscle-preserving weight loss.
How oral obesity drugs are changing treatment access: A look at semaglutide, amycretin, and orforglipron
Oral GLP-1 drugs like semaglutide, amycretin, and orforglipron are redefining obesity care. Explore trial data, payer impact, and what’s ahead for access and scale.
Can dual agonist drugs like amycretin and tirzepatide replace bariatric surgery by 2030?
Can new obesity drugs like amycretin and tirzepatide replace bariatric surgery by 2030? Discover what clinical data and cost trends reveal about the future.
Metabolics Pharma’s ENT-03 shows promising Phase 1a data in obese and type 2 diabetic patients at ADA 2025
Metabolics Pharma’s ENT-03 shows Phase 1a success in obese and diabetic subjects, with plans for Phase 1b in late 2025. Learn about its brain-based mechanism.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.